ReviewCirculation research2020
Modifiable Cardiovascular Risk, Hematopoiesis, and Innate Immunity.
Review in Circulation research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 78 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
78 citing papers in PubMed, 102 citations in OpenAlex.
- A hyperacute immune map of ischaemic stroke patients reveals alterations to circulating innate and adaptive cells.Clinical and experimental immunology · 2021Trial
- Immature Neutrophil Phenotype and Enhanced Myeloperoxidase in Male Patients With Chronic Kidney Disease and Cardiovascular Comorbidity.Acta physiologica (Oxford, England) · 2026Article
- Integrating Conventional and Emerging Approaches in Cardiovascular Risk Assessment and Management.Public health challenges · 2026Review
- Article
- Vascular Cognitive Impairment and Dementia: Clinical Features, Neuropathology, and Biomarkers.Journal of the American College of Cardiology · 2026Review
- Can Nuclear Imaging Detect Trained Immunity in Cardiovascular Disease?Arteriosclerosis, thrombosis, and vascular biology · 2026Review
- Incidence Trends and Disease Burden of Vascular Intestinal Disorders: A Population-Based Study in China and Worldwide from 1990 to 2021.Vascular health and risk management · 2026Article
- Peripheral blood myeloid-to-lymphoid ratio: a novel indicator for assessing renal and cardiovascular risks in chronic kidney disease patients-a multicenter longitudinal investigation.European journal of medical research · 2025Article
- PCSK9 inhibitors: a promising lipid-lowering strategy for kidney transplant recipients.Renal failure · 2025Review
- Metabolic Memory Resides in the Hematopoietic Marrow and in Arterial Resident Leukocytes.JACC. Basic to translational science · 2025Article
- The Impact of Flavonoids and Omega-3 in Mitigating Frailty Syndrome to Improve Treatment Outcomes in Peripheral Artery Disease (PAD) Patients.Nutrients · 2025Review
- Trained immunity in chronic inflammatory diseases and cancer.Nature reviews. Immunology · 2025Review
- Insights Into Heart-Tumor Interactions in Heart Failure.Circulation research · 2025Review
- Specialized pro-resolving mediators in vascular inflammation and atherosclerotic cardiovascular disease.Nature reviews. Cardiology · 2024Review
- Autoimmune diseases and atherosclerotic cardiovascular disease.Nature reviews. Cardiology · 2024Review
- Effects of immunological processes and mild ambient atmosphere alterations on the brain in health and disease.Neuroprotection (Chichester, England) · 2024Article
- Monocyte Single-Cell Multimodal Profiling in Cardiovascular Disease Risk States.Circulation research · 2024Article
- Review
- Leucocyte Count: Inflammatory and ROS Biomarkers of ASCVD.Journal of atherosclerosis and thrombosis · 2024Article
- Hematopoietic Stem Cells as an Integrative Hub Linking Lifestyle to Cardiovascular Health.Cells · 2024Review
18 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
Abstract
Unhealthy diet, lack of exercise, psychosocial stress, and insufficient sleep are increasingly prevalent modifiable risk factors for cardiovascular disease. Accumulating evidence indicates that these risk factors may fuel chronic inflammatory processes that are active in atherosclerosis and lead to myocardial infarction and stroke. In concert with hyperlipidemia, maladaptive immune system activities can contribute to disease progression and increase the probability of adverse events. In this review, we discuss recent insight into how the above modifiable risk factors influence innate immunity. Specifically, we focus on pathways that raise systemic myeloid cell numbers and modulate immune cell phenotypes, reviewing hematopoiesis, leukocyte trafficking, and innate immune cell accumulation in cardiovascular organs. Often, relevant mechanisms that begin with lifestyle choices and lead to cardiovascular events span multiple organ systems, including the central nervous, endocrine, metabolic, hematopoietic, immune and, finally, the cardiovascular system. We argue that deciphering such pathways provides not only support for preventive interventions but also opportunities to develop biomimetic immunomodulatory therapeutics that mitigate cardiovascular inflammation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.